Tag: NASDAQ: PIXY

  • ShiftPixy (PIXY) revealed decent Earnings results despite Covid-19 woes

    ShiftPixy (PIXY) revealed decent Earnings results despite Covid-19 woes

    ShiftPixy, Inc. (NASDAQ: PIXY), a Florida-based recruiting business that develops, operates, and offers access to an innovative, transformative network that enables work in the quickly expanding Gig Economy, released financial results for the year ended August 31, 2020.

    Owing to new consumer acquisitions and COVID-19 rehabilitation for current clients, quarterly gross billings increased to $18.7 million for Q4 2020, a sequential rise of $4.3 million or 30 percent from Q3 2020.

    Gross billings from ongoing activities were $66 million for the entire fiscal year, compared to $73 million for 2019, largely due to COVID-19 results in 2020, as well as consumer cancellations primarily during calendar 2019 in the early part of 2020.

    For Q4 2020, quarterly sales increased to $2.4 million, a sequential 20 percent improvement from Q3 2020.

    Revenues declined 17 percent to $8.6 million for the whole fiscal year, compared to $10.5 million for 2019, largely as a result of our strategic decision to change the company’s consumer attention during 2019, as well as the negative effect of the headwinds of COVID-19 growth.

    Gross profit for 2020 was $1.0 million, falling 50 percent from $1.9 million in gross profit for 2019, due to rises in workers’ compensation costs.

    Operating loss for 2020 rose from $15.6 million in 2019 by $6.0 million to $21.6 million, of which $3.5 million was a non-cash asset depletion fee attributed to previously capitalized software, together with an increase in stock-based compensation of $1.0 million.

    EBITDAS Loss increased from $14.7 million for 2019 to $16.2 million for 2020 due to reduced margins of $1.0 million and increased investment in the production of our mobile application, balanced by lowered operating costs.

    Investment in our implementation of smartphone apps and infrastructure technologies has grown from $3.1 million in 2019 to $4.2 million in 2020. Complete spending in the Human Resource Information System and smartphone apps is reportedly $20.7 million.

  • Stocks  to Watch as Caution Grips the Markets

    Stocks to Watch as Caution Grips the Markets

    The markets are headed to a weak start this morning. This comes amidst rising concerns that the market is overvalued after the S&P 500 hit an all-time despite the ongoing pandemic. The uncertainty comes after labour data consistently showing that the U.S economy was still struggling from the effects of the COVID-19 pandemic The FOMC recent minutes also point to tempered optimism.

    This environment has seen investors pile money into tech stocks that have an element of dominance in their markets, or have innovations that could help drive up their market value. Despite the current market environment, there are non-big tech stocks that are gaining momentum before markets open. Some of the top performers ahead of markets are:

    Eyepoint Pharmaceuticals Inc  [NASDAQ: EYPT]

    Eyepoint Pharmaceuticals Inc is a top performer pre-market and is up by 49%. This follows the company’s announcement that it had received $9.5 million in upfront payments for an expanded license agreement from Ocumension Therapeutics.

    The company stated that the deal was for the commercialization of YUTIQ® and DEXYCU®  in South Korea and other markets in Southeast Asia. The payment is supposed to be full compensation for all development, regulatory and commercial sale transactions. Commenting on the deal, CFO  George Elston stated that Ocumension was a major partner and shares the company’s core beliefs of pushing YUTIQ® and DEXYCU® in the treatment of several unmet medical needs.

    He added that the company was happy to expand its partnership with Ocumension in the Asian market and that the money received would be used to expand the company’s clinical projects that are currently being developed. On his part, Ocumension CEO Ye Liu stated that they looked forward to the continued development of the two products. Since the deal is a revenue boost for Eyepoint, the company is uniquely positioned for gains all through the day.

    Oragenics Inc [NYSE: OGEN]

    Oragenics Inc is another top performer pre-market and is currently up by 11 %. This follows the company’s announcement that it had signed a process development and a manufacturing deal with Avid Bioservices for a COVD-19 vaccine. Under the deal, Avid will offer Oragenics support for analytical methods drug manufacturing and method development for Terra Cov-2 (a COVID-19 vaccine).

    Commenting on the deal, Oragenics CEO  Alan Joslyn stated that with Avid’s infrastructure capabilities, they are the right partners for the development. This deal is likely to support this project all through the day.

    ShiftPixy Inc [NASDAQ: PIXY]

    ShiftPixy is up in pre-market trading and is currently up by 11%. This comes after the company announced that it was relocating its corporate headquarters to Miami, Florida. Co-founder Scott Absher stated that Miami was on their roadmap for